Company Update

Securities and Exchange Commission (“SEC”) in connection with its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) to, among other things, seek stockholder approval of a reverse stock split proposal and authorized share reduction proposal. The Annual Meeting is scheduled to be held on June 22, 2022.   Attached hereto as Exhibit 99.1, and incorporated herein by reference, is a copy of the press release.   Other Information   The Company and its directors, executive officers, and advisors may be deemed to be participants in the solicitation of proxies in connection with the proposals to be considered at the Annual Meeting. Stockholders may obtain additional information regarding the interests of those participants by reading the Company’s preliminary proxy statement filed with the SEC on April 19, 2022, and, when they become available, the Company’s definitive proxy statement and other definitive proxy materials, and the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, as filed with the SEC.   A notice of internet availability of proxy materials with instructions for accessing the definitive proxy statement will be mailed to stockholders as of the record date of April 25, 2022. Stockholders may obtain free copies of the preliminary proxy statement and the Company’s other SEC filings electronically by accessing the SEC’s home page at http://www.sec.gov. Copies can also be obtained, free of charge, upon written request to the Company, Attn: Secretary, 10025 Investment Drive, Suite 250, Knoxville, Tennessee 37932, (866) 594-5999.   Item 9.01. Financial Statements and Exhibits.   (d) Exhibits.   Exhibit Number   Description       99.1   Press Release, dated April 19, 2022.       104   Cover Page Interactive Data File (embedded within the Inline XBRL document).         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Date: April 19, 2022         PROVECTUS BIOPHARMACEUTICALS, INC.       By: /s/ Heather Raines     Heather Raines     Chief Financial Officer (Principal Financial Officer)